Charles River Laboratories International, Inc. (CRL)
Investing in Charles River (CRL)? Don't Miss Assessing Its International Revenue Trends
Evaluate Charles River's (CRL) reliance on international revenue to better understand the company's financial stability, growth prospects and potential stock price performance.
Charles River Laboratories Q4 Review: Approaching A Bottom
Charles River Laboratories Q4 Review: Approaching A Bottom
Here's What Key Metrics Tell Us About Charles River (CRL) Q4 Earnings
Although the revenue and EPS for Charles River (CRL) give a sense of how its business performed in the quarter ended December 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
CRL Stock Down Despite Q4 Earnings & Revenue Beat, Margins Rise
Charles River tops Q4 earnings and revenue estimates as margins expand, but shares dip, and organic growth declines across all segments.
Charles River Laboratories (CRL) Q4 Earnings and Revenues Surpass Estimates
Charles River Laboratories (CRL) came out with quarterly earnings of $2.39 per share, beating the Zacks Consensus Estimate of $2.33 per share. This compares to earnings of $2.66 per share a year ago.
Aquestive Therapeutics: Biology Validated, Packaging Pending - A Forensic Analysis Of The Anaphylm CRL
Aquestive Therapeutics: Biology Validated, Packaging Pending - A Forensic Analysis Of The Anaphylm CRL
What Analyst Projections for Key Metrics Reveal About Charles River (CRL) Q4 Earnings
Besides Wall Street's top-and-bottom-line estimates for Charles River (CRL), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended December 2025.
Here's How Charles River Stock Is Placed Ahead of Q4 Earnings
CRL heads into Q4 earnings with collaborations and strength in RMS and Manufacturing, even as DSA headwinds weigh on revenue expectations.
Analysts Estimate Charles River Laboratories (CRL) to Report a Decline in Earnings: What to Look Out for
Charles River (CRL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why Charles River Laboratories (CRL) is a Great Momentum Stock to Buy
Does Charles River Laboratories (CRL) have what it takes to be a top stock pick for momentum investors? Let's find out.
Charles River Laboratories International, Inc. (CRL) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Charles River Laboratories International, Inc. (CRL) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
What Makes Charles River (CRL) a New Buy Stock
Charles River (CRL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
